L iver cell adenoma (LCA) is the most important benign epithelial tumour of the liver, with an incidence of approximately 3/1 000 000 new cases per year. 1 LCA are pathogenetically related to the use of oral contraceptives, androgenic steroid therapy, and have also been reported in association with glycogen storage disease. Microscopically, the neoplasm is composed of well differentiated uniform cords of proliferating hepatocytes. Normal portal tracts are absent, tumour cells are uniform in size and shape but atypical pleomorphic cells with distorted hyperchromatic nuclei may be seen. 2 3 Transformation of LCA to hepatocellular carcinoma has been described but is extremely rare. 4 To date, the cellular and molecular mechanisms leading to uncontrolled proliferation of hepatocytes remain unclear. Great insights will come from integrating the signals of different pathways operating at cell cycle regulation, cellular proliferation, and apoptosis. 5 There is evidence that alterations in the INK4a-ARF locus, which maps to chromosome 9p21, may contribute to the development of liver tumours. [6] [7] [8] [9] The INK4a-ARF or CDKN2A locus codes for two different proteins, p16
INK4a and p14
ARF
, both involved in cell cycle regulation. 7 These two proteins are characterised by two distinct promoters and first exons spliced to a common exon 2 in different reading frames: exons 1α, 2, and 3 for p16 INK4a and exons 1β, 2, and 3 for p14 ARF . 10 The tumour suppressor gene p16 INK4a is believed to encode a negative regulatory protein that controls the progression of eucaryotic cells through the G1 phase of the cell cycle by interacting with CDK4 and inhibiting its kinase activity. 11 In the absence of functional p16 protein, CDK4 binds to cyclin D and phosphorylates pRb which stimulates entry into the S phase. 6 The p16
INK4a gene is inactivated by mutations, homozygous deletions, or gene methylation in many tumours of diverse origin.
12 p14 ARF , generated through an alternative splicing process that replaces the first exon, has been shown to function as a growth suppressor. p14 ARF specifically activates the p53 pathway. p14 ARF stabilises p53 by inhibiting MDM2 dependent p53 degradation, thereby inducing cell cycle arrest or apoptosis, depending on the stimulus. Data have shown that p14 ARF binds to MDM2 through an NH 2 terminal domain encoded by exon 1 whereas a functional domain is encoded by exon 2.
13 Activation of p14 ARF (in response to an oncogenic signal such as c-myc, activated ras) leads to localisation and sequestration of MDM2 in the nucleolar compartment, thereby stabilising p53 by preventing MDM2-p53 from undergoing ubiquitin mediated degradation. [12] [13] [14] To date, data concerning INK4a-ARF alterations in benign tumours of the liver are lacking.
To gain insights into the role of the INK4a-ARF locus in the development of LCA, mutational and expression analyses of p16 INK4a and p14 ARF were performed in a large group of patients with this disease.
MATERIALS AND METHODS

Patients and tissue samples
Twenty five patients with LCA undergoing partial hepatectomy (segmental or lobar resection) between 1990 and 1999 were included in this retrospective study.
Each tumour was re-evaluated with regard to typing (WHO 2000) . 3 In all cases, slides prepared from four different paraffin blocks of tissue, sampled from different tumour areas, were examined.
DNA samples
For each LCA sample, the histopathological lesions of interest were first identified on routinely stained slides. Parallel sections were cut with the microtome set at 6 µm, and the slides dried overnight at 37°C. Corresponding areas of interest were delineated and microdissected after rapid staining with haematoxylin and eosin. Thereafter the tissue was scraped off the slide (sections were covered by 25 µl of Tris buffer 0.05 mol) with the tip of a sealed glass pipette and then sucked into a microcapillary tube. Tissue samples were placed in Eppendorf tubes and incubated with proteinase K at 37°C overnight. Proteinase K activity was inactivated by heating to 95°C for 10 minutes. For DNA extraction, standard methods were used: after incubation with proteinase K at 37°C overnight, the tissue was extracted twice in phenol and twice in chloroform, followed by ethanol precipitation.
Methylation status of the INK4a-ARF locus
The CpG WIZ p16 methylation assay kit was used (OncorInc, Gaithersburg, Maryland, USA) according to the manufacturer's instructions. After an initial bisulphide reaction to modify the DNA, polymerase chain reaction (PCR) amplification with specific primers was performed to distinguish methylated from unmethylated DNA. Primers specific for unmethylated p16 (5-TTATTAGAGGGTGGGGTGGATTGT-3, 5-CAACCCCAAACCA CAACCATAA-3) or methylated p16 (5-TTATTAGAGGGTG GGGCGGATCGC-3, 5-GACCCCGAA CCGCGACCG TAA-3) were used. DNA (7 µg/100 µl) was denatured by 0.2 M NaOH for 10 minutes at room temperature. DNA Modification Reagent I was added, incubated for 24 hours at 50°C, and subsequently purified by DNA Modification Reagents II and III in the presence of 50 µl of water. The bisulphide modification of DNA was completed with 0.3 M NaOH treatment for five minutes followed by ethanol precipitation. For hot start PCR, the PCR mixture contained Universal PCR Buffers (1×9, 4dNTPs (1.25 nM)), and U or M primers (300 ng each per reaction). Annealing temperature was 65°C for 30 cycles. The PCR product was directly electrophoresed on a 3% agarose gel, stained with ethidium bromide, and visualised under UV illumination. Bisulphide converted DNA from corresponding normal liver tissue from each patient served as a negative control, as indicated by the presence of the unmethylated but not the methylated band. To control the efficacy of bisulphide treatment, a primer set was used for unmodified or wild-type ("w") (5-CAGAGGGTGGGGCGGACCGA-3 and 5-CGGGCCGCG GCCGTGG-3). In the event of insufficient bisulphide modification of DNA, the wild-type primers should have been amplified.
The methylation pattern in the CpC islands of the p14 ARF were determined by primers designed for either methylated or unmethylated DNA. 15 The primers spanned six CpG sites within the 5′ regions of the gene. The 5′ positions of the sense unmethylated and methylated primers correspond to 195 and 201 bp of GenBank sequence number LA1934. The primer sequences for the unmethylated reaction were 5′TTTT TGGTGTTAAAGGGTGGTGTAGT-3′ (sense) and 5′-CACAAA AACCCTCACTCACAACAA-3′ (antisense), yielding a PCR product of 132 bp. The primer sequences for the methylated reaction were 5′-GTGTTAAAGGGCGGCGTAGC-3′ (sense) and 5′-AAAACCCTCACTCGCGACGA-3′ (antisense), which amplify a 122 bp product. 12 Placental DNA treated with methyltransferase was used as a positive control for methylated alleles. The PCR products (15 µl) were electrophoresed on a 8% polyacrylamide gel, stained, and directly visualised.
In addition to methylation specific PCR (MSP), a second approach was used to determine the methylation status of p14 ARF and p16
INK4a , the restriction enzyme related-PCR (RE-PCR), as described by Chaubert and colleagues. 9 Genomic DNA was digested with four methyl sensitive (HpaII, NaeI, EaglI, and Ksp1) and one non-methyl sensitive (MspI) restriction enzyme. After chloroform/phenol extraction and precipitation, PCR amplification of a 316 bp fragment of p14 ARF exon 1 containing one HpaII and one Ksp1 site were amplified by PCR. The following primers were used: forward: GCCTGCG-GGGCGGAGAT; reverse: GCGGCTGCTGCCCTAGA. For p16 INK4a , a 150 bp fragment of exon 1 containing two HpaII and one Ksp1 site were amplified by PCR. The primer sets were GGGAGCAGCATGGAGCCG (forward) and CTGGATCG-GCCTCCGACCGTA (reverse).
Undigested placental and tumour DNA was used as a control. Cases were considered positive by RE-PCR when PCR amplification was obtained after digestion with one of the methyl sensitive restriction enzymes used ( fig 1A, B) . Two CpG dinucleotides of exon 1 of p14 ARF and three from p16 INK4a exon 1 were analysed. In case of a methylated p16
INK4a gene, a real time quantitative MSP based on continuous optical monitoring of the progress of a fluorogenic PCR was performed. The bisulphite modified DNA was amplified using the following probes and primers: E5: 5′-CRTTATCTACTCTCCCCCTCTCC; E6: 5′-GGTTGGTTATTAGAGGGTGGGG; M probe: 5′-FAM-AACCGCCGAACGCACGC-TAMRA; and U probe: 5′-FAM-CAACCACCAAACACACACAATCCACC-TAM-RA. The sensitivity and specificity of real time PCR was determined using cloned fragments of bisulphite modified DNA as a fragment.
Multiplex RT-PCR
To compare relative levels of p16
INK4a and p14 ARF mRNA, multiplex reverse transcription-PCR (RT-PCR) was performed. Total RNA was extracted from 30 µg of microdissected LCA tissue by TRIzol reagents (Gibco BRL, Rockville, Maryland, USA). After ethanol washing and drying, RNA was suspended in 60 µl of diethyl pyrocarbonate treated water. After concentration determination, 2 µg of total RNA were subjected to a reverse transcription reaction using random oligonucleotide primers and superscript II reverse transcriptase (Gibco BRL) in a 20 µl reaction volume for 60 minutes at 42°C. The RT reaction product (1 µl) was then amplified by PCR using the forward primers of exons 1α and 1β and the reverse primer for exon 2 of the p16
INK4a -p14 ARF gene. The primers were as follows: forward exon 1α (sense 1): 5′-GCTGCCCACGCACCGAATA-3; exon 1β (sense 2): 5′CCCTCGTGCTGATGCTACTGA-3′; and reverse primer (antisense) 5′ACCACCAGCGTGTCCAGGAA-3′. Hot start PCR was performed for 35 cycles (95°C for 45 seconds, 57°C for 45 seconds, and 72°C for 60 seconds). The sizes of the products were 179 bp for p16 INK4a and 200 bp for p14 ARF , respectively. PCR products were electrophoresed on a 2% agarose gel and stained. β-actin amplification was performed to show RNA quality.
Allelic dosage analysis of loss of heterozygosity and homozygous deletion, and DNA sequencing for the INK4a-ARF (CDKN2A) locus Allelic dosage analysis of the p14 ARF and p16
INK4a genes was performed using differential PCR. DNA fragments were amplified in exon 1β of p14 ARF , exon 3 of p16 INK4a , and exon 2 using the following primers: p14arf exon 1b: ARF2F 5′-CTCGTGCTGATGCTACTAGAG-3′ and ARF2R 5′-AAGTCGTT GTAACCCGAATG-3′; p16 exon 3: p16ex3F: 5′-CGATTGAA AGAACCAGAGAG-3′ and p16ex3R 5′-ATGGACATTTACGG TAGTGG-3′; interferon γ: INFGF2dF 5′-GCAGGTCATTCAGA TGTAGC-3′ and INFG2RdR 5′-AGAGCACAAACAGAGGATGA-3′. As a negative control, a glioblastoma cell line (LNZ343) with a known deletion of the INK4a-ARF locus was used. For positive controls, the hepatocellular carcinoma cell line HepG2 with an intact INK4-ARF locus was analysed. The ratio of DNA fragment intensity in HepG2 between exon 1b or exon 3 and the internal control interferon γ was used to normalise the results. Hemizygous deletion was diagnosed if the ratio of the tumour sample was 50% of the one found in HepG2. If the ratio was less than 40%, the tumour sample was considered to harbour a homozygous deletion (fig 2) . To control the data for gene dosage analysis, microsatellite analysis using nine microsatellites of chromosome 9p21 was performed, as described previously. 16 The markers used were D9S161, D9S126, D9S171, D9S1752, D9S1748, D9S1747, D9S1749, D9S1751, and IFNA, and were obtained from Research Genetics (Hubtsville Alabama, USA) (fig 3) .
Single strand conformational polymorphism (SSCP) analysis is a technique for the detection of mutations based on the three dimensional conformation taken by a single strand of DNA in a INK4a analysis using methylation specific polymerase chain reaction (MSP). Bisulphite treated DNA (which changes the unmethylated but not the methylated cytosines into uracil) is subjected to PCR amplification using primers designed to anneal specifically to the methylated bisulphite modified DNA. MSP results are expressed as unmethylated p16 specific bands (U) or methylated p16 specific bands (M). Bisulphite converted DNA from normal corresponding liver tissue (N) served as a negative control, as indicated by the presence of the U but not the M band. Similar to (B), methylation of p16 group.bmj.com on January 12, 2018 -Published by http://mp.bmj.com/ Downloaded from non-denaturing environment. Coding sequences and flanking intronic sequences of exons 1α, β, and 2 of the INK4a-ARF gene were analysed by PCR-SSCP. Primer sequences for exons 1α, β, and 2 have been described previously. 16 Exon 1β was analysed through two overlapping PCR products generated with the primer pairs P14F1 (5′ TCAGGGAAGGGCGGGTGCG 3′) and P14R1 (5′ GCCGCGGGATGTGAACCA 3′), which generated a 245 bp product, and the primer pair P14F2 (5′ GCCGCGAGTGAGGGTTTT 3′) and P14R2 (5′ CACCGCGGTTATCTCCTC 3′), which generated a 257 bp product. The primers were labelled with 32 P-ATP and each sample was subjected to PCR analysis (denaturing for 30 seconds, annealing for 45 seconds, extension for 30 seconds at 94°C, 55-60°C, and 72°C, respectively). The PCR products were electrophoresed, and the gels dried and autoradiographed. Variant SSCP bands were cut out from the gel and the DNA eluted. Variant bands and 3 µl of the eluted DNA were used as templates for unlabelled PCR. After purification of the PCR products, sequencing analysis was performed using the DNA Sequenase Kit (Amersham, Germany) and an automatic sequencing analyser (ABI 373; Applied Biosystems-Perkin-Elmer, Germany). All mutations found were confirmed by direct sequencing of the amplified tumour and corresponding non-tumorous DNA to identify germline mutations and polymorphisms.
Immunohistochemical analysis and assessment
Immunohistochemical analysis was performed as described previously. 16 In all cases tumour and non-neoplastic liver tissue was examined.
The following antibodies were used: p16 (polyclonal; rabbit, dilution 1:500; Pharmingen, San Diego, California, USA), and p14 (polyclonal; rabbit, dilution 1:100; Zymed Laboratories, South San Francisco, California, USA).
Sections known to stain positively were included in each batch and negative controls were also performed by replacing the primary antibody with mouse or goat ascites fluid (Sigma-Aldrich Biochemicals, St Louis, Missouri, USA).
RESULTS
Analysis of INK4a-ARF deletions and mutations
Twenty five normal/tumour pairs were interpreted for allelic dosage analysis (table 1, fig 2) . The allelic balance of the two genes was determined using the interferon γ gene as an internal control (fig 2) . The two genes, p14 ARF and p16 INK4a , were expressed in all cases examined; deletions were not observed. No exclusive loss of either p 16INK4a or p14 ARF was found in our tumours. Loss of heterozygosity analysis revealed an identical status of the microsatellite markers used in paired samples of LCA and corresponding liver (fig 3) .
Mutations of exons 1 and 2 were analysed by SSCP-PCR followed by direct sequencing of the cases with anomalous migrating bands. In nine cases, abnormal bands were visible. However, we failed to detect specific mutations within both exons. In one case, a polymorphism was identified in normal liver but not within LCA tissue (c442G >A; A148T).
Methylation status of the p14
ARF and p16 INK4A genes Promoter methylation of p14 ARF was present in 3/25 cases (12%). In all patients, corresponding non-neoplastic liver tissue was also analysed; no p14 ARF promoter methylation was observed in any case. Analysis of the methylation status of the adjacent p16
INK4a gene revealed that 6/25 LCA (24%) examined showed aberrant methylation at the 5′CpG island. Despite microdissection, amplification of unmethylated templates was also detected to some degree, probably because of contaminated normal intratumorous tissue (fibroblasts, endothelial cells, inflammatory cells ARF and p16 INK4a . Results of differential polymerase chain reaction technique, as described in the text. Negative control: LNZ343 with known deletion of the INK4a-ARF locus. Positive control: HepG2 with an intact INK4-ARF locus. The ratio of DNA fragment intensity in HepG2 between exon 1β or exon 3 and the internal control interferon γ (IFN-γ) was used to normalise the results. In patient Nos 2, 4, 10, and 11, the ratio between exon 1β or exon 3 and IFN-γ was 70-100% of the ratio found in HepG2, suggesting that there was no loss at the INK4a-ARF locus. In human cells, transcriptional silencing usually involves methylation of CpG rich sequences (CpG islands) in the promoters of affected genes. Such silencing is clonal and thought to be physiologically irreversible in somatic cells. Neoplastic cells often display aberrant methylation of multiple genes, including genes that regulate critical processes such as cell cycle control, DNA repair, and angiogenesis. 12 18 24 The cause(s) of aberrant promoter methylation in neoplastic cells remains to be elucidated. It has been proposed that age related methylation identifies and contributes to an acquired predisposition to neoplasia (for example, colon cancer) because it parallels an age related increased cancer incidence and has the potential to alter the physiology of aging cells and tissues. 25 26 This hypothesis predicts that higher levels of age related methylation may be present in conditions of rapid cell turnover that mimic premature aging. In LCA, an increase in cellular proliferation is often visible histologically. The proliferative activity of the neoplastic hepatocytes is significantly higher than in adenoma surrounding non-neoplastic liver tissue. Therefore, we hypothesise that methylation and consecutive silencing of the p16
INK4a and p14 ARF promoter may cause induction of increased cell turnover via affecting the G1/S phase transition of the cell cycle. In contrast with Rashid et al who found aberrant methylation of p16
INK4a in approximately 73% of tubulovillous colon adenoma, 28 a clear precancerous lesion, we detected aberrant methylation only in 24% of LCA. Together with the observation that altered methylation is also observed in liver cirrhosis, 24 our data favour the hypothesis that methylation is a phenomenon of increased cellular proliferation and immortalisation rather than a conditio-sine-quanon of malignant transformation. 
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